Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.Biopharmaceutical company Replidyne has reported that preclinical studies of REP3123 have shown the compound to inhibit growth and prevent spore-forming of the Gram-positive Clostridium difficile bacterium without inhibiting other key organisms that are essential for normal intestinal functioning. C. difficile-associated disease.
Subscribe to our email newsletter
In preclinical studies, REP3123 was superior to two agents widely used to treat C. difficile infections, vancomycin and metronidazole, in preventing the organism from forming spores. The study results suggest that REP3123 has the potential to reduce the presence of spores in the intestine, subsequently preventing dissemination into the environment, thereby potentially reducing outbreak and relapse rates.
Stuart Johnson, associate professor of medicine, Stritch School of Medicine, Loyola University and the Hines VA Medical Center in Chicago said: “CDAD is a challenging disease for many reasons, including the difficulty associated with eradication of Clostridium difficile and its spores from the environment. These results demonstrating that REP3123 has a direct impact on inhibiting spore-formation of C. difficile bacteria are highly promising and clinically relevant.”
Kenneth Collins, president & CEO said: “Through a novel mechanism of action that inhibits growth and targets both sporulation and toxin production, REP3123 could be a future treatment option that tackles the main challenges associated with treating CDAD: high rates of relapse and new outbreaks.”